Ultra-Late Osteosarcoma Recurrences: An Analysis of 17 Cooperative Osteosarcoma Study Group Patients with a First Recurrence Detected More Than 10 Years After Primary Tumor Diagnosis
Publication: Journal of Adolescent and Young Adult Oncology
Volume 12, Issue Number 1
Abstract
Purpose: Osteosarcoma is a typical malignancy of childhood and adolescence. Recurrences usually occur early, but rarely may arise after decades of remission. Little is known about these very late events and we set out to fill this knowledge gap.
Methods: The database of the Cooperative Osteosarcoma Study Group (COSS) was searched for patients with a first recurrence of a high-grade central osteosarcoma occurring >10 years after diagnosis of the primary disease. Identified patients were analyzed for demographic, tumor-, and treatment-related factors as well as outcomes.
Results: Among a total of 1,178 10-year relapse-free survivors, 17 affected patients were identified. Only five of these had a documented good response to initial chemotherapy. No presenting factor was identified to predict these very late events. Prognosis was generally very poor despite intensive multimodal therapy. Inoperability of the recurrences seems to have constituted a major limiting factor.
Conclusion: Osteosarcoma patients should be followed for potential recurrences for well >10 years from initial diagnosis. Only through such an extended truly long-term follow-up and a structured transition of young patients can these be detected while they are still operable and, hence, potentially curable.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520–36.
2. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–68.
3. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21(4):710–5.
4. Spraker-Perlman HL, Barkauskas DA, Krailo MD, et al. Factors influencing survival after recurrence in osteosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2019;66(1):e27444.
5. Maeda R, Isowa N, Onuma H, et al. Appearance of lung metastasis from osteosarcoma 21 years after initial treatment. Gen Thorac Cardiovasc Surg. 2008;56(12):613–5.
6. Ellegast J, Barth TF, Schulte M, et al. Metastasis of osteosarcoma after 16 years. J Clin Oncol. 2011;29(3):e62–6.
7. Kaneuchi Y, Hakozaki M, Yamada H, et al. Very late relapse of high-grade osteosarcoma: a case report and review of the literature. Medicine (Baltimore). 2020;99(29):e21206.
8. Strauss SJ, McTiernan A, Whelan JS. Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer. 2004;43(6):692–7.
9. Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(24):1709–20.
10. Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2009;152:289–308.
11. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50.
12. Salzer-Kuntschik M, Delling G, Brand G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie. 1983;4:135–41.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
14. Jaffe N, Pearson P, Yasko AW, et al. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer. 2003;98(11):2457–66.
15. Franke M, Hardes J, Helmke K, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011;56(5):771–6.
16. Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6(5):724–34.
17. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer. 1998;77(3):370–7.
18. Andreou D, Bielack SS, Carrle D, et al. The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol. 2011;22(5):1228–35.
19. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.
Information & Authors
Information
Published In
Journal of Adolescent and Young Adult Oncology
Volume 12 • Issue Number 1 • February 2023
Pages: 76 - 82
PubMed: 36454220
Copyright
Copyright 2023, Mary Ann Liebert, Inc., publishers.
History
Published online: 14 February 2023
Published in print: February 2023
Published ahead of print: 28 November 2022
Topics
Authors
Author Disclosure Statement
L.K. reports having acted as advisory board member for Amgen, Agios, Bayer, and Novartis. T.W. reports grants from Orthopediatrics and Orthofix. S.S.B. reports having acted as consultant and/or advisory board member for Bayer Healthcare, Boehringer Ingelheim, Hoffmann-La Roche, Ipsen, and Eli Lilly. All these financial relationships were outside the scope of submitted study. S.H.-N., T.K., D.B., C.B., G.F., T.v.K., M.K., R.M.-S., R.S., and B.S. report no conflicts of interest.
Funding Information
The studies from which these patients originate were supported by Deutsche Krebshilfe (DKH T10/96/Bi, DKH 70-02160, DKH 50-2723-Bi2), Deutsche Forschungsgemeinschaft (BI 1045/1-1, BI 1045/1–2), Fördergemeinschaft Kinderkrebs-Zentrum Hamburg, and Förderkreis krebskranke Kinder Stuttgart.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.